AB Science advances Ultra-Selective SYK Kinase Inhibitor

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AB Science advances Ultra-Selective SYK Kinase Inhibitor into Full Preclinical Development

PARIS, Nov. 28, 2014 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), reported the advancement of a novel, small molecule SYK kinase inhibitor named AB8779 into full preclinical development.

Spleen tyrosine kinase (SYK) is a tyrosine kinase that is an important mediator of signaling in a variety of inflammatory cells, including mast cells, macrophage, dendritic cells (DC), natural killer (NK) cells, neutrophils, and B-cells.

Inhibition of SYK appears to be a good therapeutic strategy for B-cell malignancies, including non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as for certain inflammatory diseases such as asthma and rheumatoid arthritis.

The compound is entirely owned by AB Science and is brought forward into formal development as part of a strategy to bring potent and selective compounds from the proprietary drug discovery technology through clinical development and into commercialization.

AB Science has developed a proprietary technology that improves predictability of activity and selectivity of tyrosine kinase inhibitors, allowing for the design and retain of compounds with very high selectivity for designated kinases and stringent tests to avoid potential class-effect toxicities.

The aim of AB Science with AB8779 has been to design a potent and selective SYK inhibitor with good safety profile with no cardiac and neuronal toxicity.
In vitro , AB Science SYK inhibitor AB8779 was shown to be as potent as tamatinib (R406), the active metabolite of anti-SYK inhibitor fostamatinib (Rigel) (IC 50 = 0.04 µM and 0.02 µM, respectively) but exhibited an ultra-selective profile, as illustrated below from DiscoveRx.

Treespot TM interaction maps of AB Science compounds AB8779 and masitinib (AB1010) compared to fostamatinib (R406)

Preclinical data demonstrate that AB Science SYK inhibitor AB8779 has biological activity in vitro and in vivo in inflammatory murine models of asthma and rheumatoid arthritis. Additionally, it was shown that AB8779 induces apoptosis of B-cell chronic lymphocytic leukemia cells and has anti-tumoral activity in vivo in a mouse model of mantle cell lymphoma (MCL). It was further demonstrated that AB8779 has no cardiotoxicity in vitro on both human and rat cardiomyocytes. In vitro safety pharmacology and pharmacokinectics studies have also demonstrated that AB Science SYK inhibitor AB8779 has good bioavailability and an absence of mutagenic activity.

Alain Moussy, co-founder and CEO of AB Science commented: " Our compound exhibits strong and very high selective anti-SYK activity in vitro and in vivo with good safety and pharmacokinetic profiles. Our findings show that AB8779 could represent a clear efficacy and safety advance for the treatment of certain forms of lymphoma as well as for mast cell diseases. The design of this new drug candidate has been made possible thanks to our proprietary drug discovery technology which prioritizes selectivity ".

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a  class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in humans and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing thirteen phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer's disease, progressive forms of multiple sclerosis, and Amyotrophic Lateral Sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website: www.ab-science.com

This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.

AB Science - Financial Communication & Media Relations
contact@ab-science.com

AB Science EN http://hugin.info/155655/R/1875332/660802.pdf

HUG#1875332

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 95

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 86

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 102

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 121

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look

Updated Category News Views 75

A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 111

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 72

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 139

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 119

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading

Top 5 Most Recently Viewed Articles

Appian Partners with Children's National to Elevate Healthcare

Updated Category News Views 87

Appian Teams Up with Children’s National Hospital Appian, known for its cutting-edge software solutions, is excited to share its new collaboration with Children’s National Hospital, one of the top names in pediatric healthcare. This partnership aims to raise awareness and gather essential resources for children's health. Appian is dedicated to enhancing the healthcare...

Continue Reading
Deutsche Bank Predicts ECB Rate Cuts Amid Falling Inflation

Updated Category News Views 101

Deutsche Bank dropped a prediction back in late 2023 that the European Central Bank (ECB) was gearing up for interest rate cuts this October. Traders perked up when they caught wind of unexpected dips in inflation figures from the eurozone noted earlier that September. Why the Cut? Inflation Insights Unpacked Analysts at Deutsche Bank, led by chief economist Mark Wall,...

Continue Reading
Vipshop's Financial Performance Analysis for 2024 Revealed

Updated Category News Views 390

Vipshop's Financial Insights for 2024 Vipshop Holdings Limited (NYSE: VIPS), a prominent online discount retailer in the Chinese market, has recently shared its unaudited financial results for the quarter and full year that concluded on December 31, 2024. Despite encountering challenges over the previous year, Vipshop's performance indicates resilience and potential...

Continue Reading
Boston University and Infocap Partner for Digital Transformation

Updated Category News Views 207

Boston University's Digital Business Institute Partners with Infocap BOSTON--The Digital Business Institute (DBI) at Boston University Questrom School of Business and Infocap AI Corp, a leader in human-centric automation, have announced a strategic partnership aimed at revolutionizing digital transformation across the banking sector. This collaboration is particularly...

Continue Reading
Disclosure and Investment Position Overview for Keywords Studios

Updated Category News Views 116

Understanding Disclosure and Investment Positions In the complex world of stock market investments, transparency is crucial. This is especially true for organizations involved with Keywords Studios PLC, a leading player in the gaming services sector. This article seeks to shed light on the recent disclosures and key investments associated with this prominent company. Key...

Continue Reading